tradingkey.logo

scPharmaceuticals Inc

SCPH
5.670USD
0.000
Cierre 11/07, 16:00ETCotizaciones retrasadas 15 min
302.16MCap. mercado
PérdidaP/E TTM

Más Datos de scPharmaceuticals Inc Compañía

scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.

Información de scPharmaceuticals Inc

Símbolo de cotizaciónSCPH
Nombre de la empresascPharmaceuticals Inc
Fecha de salida a bolsaNov 17, 2017
Director ejecutivoMr. John H. Tucker
Número de empleados162
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 17
Dirección25 Burlington Mall Road, Suite 203
CiudadBURLINGTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal01803
Teléfono16175170730
Sitio Webhttps://www.scpharmaceuticals.com/
Símbolo de cotizaciónSCPH
Fecha de salida a bolsaNov 17, 2017
Director ejecutivoMr. John H. Tucker

Ejecutivos de scPharmaceuticals Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Michael E. Castagna
Mr. Michael E. Castagna
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Chris Prentiss
Mr. Chris Prentiss
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. David Thomson
Mr. David Thomson
Company Secretary, Director
Company Secretary, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Michael E. Castagna
Mr. Michael E. Castagna
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Chris Prentiss
Mr. Chris Prentiss
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. David Thomson
Mr. David Thomson
Company Secretary, Director
Company Secretary, Director
--
--

Desglose de ingresos

Sin datos
Sin datos
Por negocio
Por región
Sin datos

Estadísticas de accionistas

Actualizado: vie., 7 de nov
Actualizado: vie., 7 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
OrbiMed Advisors, LLC
11.29%
Rubric Capital Management LP
8.57%
Lytton (Laurence W)
5.49%
Lundbeckfond Invest
5.34%
Glazer Capital, LLC
4.61%
Otro
64.71%
Accionistas
Accionistas
Proporción
OrbiMed Advisors, LLC
11.29%
Rubric Capital Management LP
8.57%
Lytton (Laurence W)
5.49%
Lundbeckfond Invest
5.34%
Glazer Capital, LLC
4.61%
Otro
64.71%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
21.37%
Hedge Fund
19.70%
Private Equity
12.33%
Investment Advisor/Hedge Fund
8.20%
Individual Investor
5.85%
Research Firm
3.74%
Venture Capital
2.30%
Bank and Trust
0.14%
Insurance Company
0.02%
Otro
26.36%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
203
36.40M
67.81%
-13.56M
2025Q2
207
43.86M
83.06%
-9.87M
2025Q1
220
46.17M
87.73%
-9.39M
2024Q4
216
48.09M
96.18%
-7.84M
2024Q3
205
45.54M
91.15%
-1.25M
2024Q2
187
32.09M
87.10%
-11.64M
2024Q1
180
29.20M
80.96%
-13.79M
2023Q4
174
29.67M
82.49%
-9.34M
2023Q3
165
32.24M
89.90%
-5.09M
2023Q2
160
30.81M
85.97%
-2.10M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
OrbiMed Advisors, LLC
6.06M
11.29%
--
--
Jun 30, 2025
Rubric Capital Management LP
4.60M
8.57%
-173.02K
-3.62%
Jun 30, 2025
Lytton (Laurence W)
2.94M
5.49%
+1.12M
+61.35%
Sep 30, 2024
Lundbeckfond Invest
2.86M
5.34%
+2.86M
--
Sep 30, 2024
Glazer Capital, LLC
2.47M
4.61%
+2.47M
--
Sep 02, 2025
The Vanguard Group, Inc.
1.84M
3.42%
-157.11K
-7.88%
Jun 30, 2025
Luther King Capital Management Corp.
3.54M
6.6%
+420.00K
+13.46%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.99M
3.7%
-164.72K
-7.65%
Jun 30, 2025
Morgan Stanley & Co. LLC
1.66M
3.1%
+13.12K
+0.80%
Jun 30, 2025
5AM Ventures
1.20M
2.24%
--
--
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.5%
iShares Micro-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.5%
iShares Micro-Cap ETF
Proporción0.04%
ProShares Ultra Nasdaq Biotechnology
Proporción0.03%
Invesco Nasdaq Biotechnology ETF
Proporción0.03%
Global X Russell 2000 ETF
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
iShares Russell 2000 Growth ETF
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI